Alnylam Pharma (ALNY) Tops Q3 EPS by 43c, Misses on Revenue; Offers FY24 Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $239.56 -2.42%
EPS Growth %: -39.0%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -39.0%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($0.50), $0.43 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $500.92 million versus the consensus estimate of $532.36 million.
The company reiterated 2024 financial guidance, including combined Net Product revenues of $1,575 million to $1,650 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Trump announces security deal with Denmark on Greenland
- RBC Capital Reiterates Sector Perform Rating on Freehold Royalties Ltd. (FRU:CN) (FRHLF)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
